Brian N. Cunningham, MD – Business Advisor
Brian N. Cunningham, MD has been extensively involved in Bay City Capital’s investment activities since he joined The Pritzker Organization in 2004. Dr. Cunningham has served in various operational roles with a number of Bay City Capital portfolio companies, most notably Madrigal Pharmaceuticals. Dr. Cunningham has been instrumental in the execution of numerous collaborations and licensing deals, provided oversight of portfolio company financial functions including budgetary responsibilities, and advised on clinical development strategies. Prior to joining The Pritzker Organization, Dr. Cunningham was a Consultant with L.E.K. Consulting, focusing in the biopharmaceutical and medical device sectors. Prior to joining L.E.K., Dr. Cunningham was a Research Fellow at the Cleveland Clinic Foundation in the Department of Plastic and Reconstructive Surgery. After matriculating in a combined BS/MD program, he received his medical degree with honors in 2001 from Northeastern Ohio University College of Medicine.
Jonathan A. Epstein, MD – Scientific Founder
Dr. Epstein is currently the William Wikoff Smith Chair in Cardiovascular Research, Chairman of the Department of Cell and Developmental Biology and the Scientific Director of the Penn Cardiovascular Institute at the University of Pennsylvania. Dr. Epstein’s research has focused on the molecular mechanisms of cardiovascular development and implications for understanding and treating human disease. His group has been at the forefront of utilizing animal models of congenital heart disease to determine genetic and molecular pathways required for cardiac morphogenesis, with implications for pediatric and adult cardiovascular disease. Stem cell, angiogenesis and epigenetic studies have had direct implications for the development of new therapeutic agents for heart failure and myocardial infarction. Dr. Epstein is a practicing cardiologist and cares for patients in the cardiac intensive care unit at the Philadelphia Veterans Administration Hospital. Dr. Epstein graduated from Harvard College in 1983, Harvard Medical School in 1988 and completed his Residency and Fellowship in Medicine and Cardiology at the Brigham and Women's Hospital, where he also completed an HHMI Postdoctoral Fellowship in Genetics. Dr. Epstein is a member of the American Academy of Arts and Sciences, American Association of Physicians, Past President of the American Society for Clinical Investigation and a member of the Institute of Medicine of the National Academy of Sciences. He serves on several editorial boards, and is a past Deputy Editor of the Journal of Clinical Investigation. Dr. Epstein was a founding co-director of the Penn Institute for Regenerative Medicine in 2007.
Peter J. Gruber, MD, PhD – Scientific Founder
Peter J. Gruber, MD, PhD, is a Professor and the Chair of Cardiothoracic Surgery at the University of Iowa Hospitals and Clinics. Dr. Gruber joined the faculty in January 2014. Prior to this appointment, Dr. Gruber was an Associate Professor and Section Chief in Pediatric Cardiothoracic Surgery at the University of Utah. Dr. Gruber joined the Iowa faculty in 2011 as Pediatric Section chief, in the Division of Cardiothoracic Surgery and is a diplomate of the American Boards of Surgery, Thoracic Surgery, and Congenital Cardiac Surgery Subspecialty. He devoted 25% of his time to research and was an investigator in the Molecular Medicine program and was co-Director of the Heart Center at Primary Children’s. He is Principal Investigator on a 5-year ($1,675,000) NIH National Heart, Lung and Blood Institute (NHLBI) grant titled: Histone deacetylase-mediated reduction of ischemia reperfusion injury. He reviews proposals for the NIH, AHA, and the Children's Research Foundation and reviews for numerous journals including Circulation, Development, Journal of Clinical Investigation, Journal of Molecular and Cellular Biology, and The Annals of Thoracic Surgery. He is a committee member on the American Board of Thoracic Surgery, American Society for Clinical Investigation, and is a Surgical Co-Chair for the Pediatric Critical Care Congress. He has published numerous manuscripts book chapters and lectures internationally.
Doug Given, MD, PhD, MBA – Business Advisor
Dr. Given has served as an investment professional on more than 45 investments at Bay City Capital, a Silicon Valley-based venture capital firm focusing on life sciences industry investments. Currently an active advisor at Bay City, Doug also participates on the board of directors of both public and private companies, currently serving as chairman of the board at both Arrowhead Research (NASDAQ: ARWR) and Vivaldi Biosciences. He has advised numerous VC funds in Australia, US and Israel. Over his career, Dr. Given has directly participated in the development of more than 15 top-selling drugs, biologics, diagnostics, imaging agents, and medical devices. He has overseen the drug development process at Schering Plough Research, Monsanto/G.D. Searle Research Laboratories, and Lilly Research Laboratories. Dr. Given has also led large teams through high growth, IPO, M&A, restructuring and exit processes as a C-level executive and board director. He has served as CEO of Progenitor, NeoRX, VIA Pharmaceuticals and Vivaldi Biosciences and as a Director of Aksys Inc, Sembiosys Genetics Inc and numerous additional private company boards. Dr. Given retains strong ties to world-class academic institutions. He is an advisor to the University of Chicago’s Pritzker School of Medicine, where he received the distinguished alumnus award in 2011. Doug is also an advisor to the Harvard School of Public Health and the Johns Hopkins Bloomberg School of Public Health.
Thomas M. Gorrie, PhD, MS – Business Advisor
Dr. Gorrie is a multitalented business adviser for global organizations in the health care sector providing expertise in the areas of government relations, general management, medical products, health policy, investments, and sales and marketing. A chemist by training, he began his career at Johnson & Johnson (J&J) as a senior research scientist in 1972, and over the next 35 years ascended to senior positions in research and development, marketing and sales, international, general management, and venture capital. Prior to his retirement, his last role as a corporate officer at J&J was as vice president of government affairs and policy responsible for federal, state, and international relations for the company. Dr. Gorrie currently serves as a trustee of Duke University and as chairman of the board for the Duke University Health System. He is a member of the Robert Wood Johnson Foundation Board of Trustees. He is a nonexecutive director of the British Standards Institution in the United Kingdom. Dr. Gorrie is distinguished executive in residence and adjunct professor at Rutgers University School of Business. He is a senior adviser to the China Association of Enterprises with Foreign Investments in Beijing. He also has written many peer-reviewed scientific articles, holds two patents, has made numerous presentations on broad subjects globally, and co-edited the book Ethics and the Pharmaceutical Industry. Dr. Gorrie received a PhD and an MS in chemistry from Princeton University, and earned a BA in chemistry from Rutgers University. He completed postdoctoral studies at the Swiss Federal Institute of Technology in Zurich.
Robert A. Kloner, MD, PhD, FACC – Scientific Advisor
Dr. Kloner is Professor of Medicine, in the Cardiovascular Division, Keck School of Medicine, at the University of Southern California, in Los Angeles (since 1988). He is also Director of Research of the Heart Institute of Good Samaritan Hospital in Los Angeles (since 1987) and attending cardiologist at Los Angeles County/University of Southern California Medical Center. Dr. Kloner received his MD in the Honors Program in Medical Education and PhD (Experimental Pathology) degrees from Northwestern University Medical School where he trained in the laboratory of Dr. Robert Jennings. He completed internship and residency in internal medicine at Peter Bent Brigham Hospital in Boston, Massachusetts. Additional training included clinical and research fellowships in medicine and cardiology (with Drs. Eugene Braunwald and Peter Maroko) at Harvard Medical School and Brigham and Women’s Hospital. Dr. Kloner is a fellow of the American College of Cardiology, an Inaugural Fellow of the Council on Basic Cardiovascular Sciences of the AHA, and was elected to the American Society of Clinical Investigation. Dr. Kloner has made major contributions to the understanding of heart disease, including such concepts as no-reflow phenomenon, stunned myocardium, limitation of myocardial infarct size, post-reperfusion apoptosis, reperfusion phenomena and triggers of cardiovascular events. Other major research interests include cardiac cell transplantation, the effect of toxins on the heart, preventative cardiology, hypertension, and PDE5 inhibition. A frequent contributor to the medical and scientific press, Dr. Kloner has authored or co-authored 667 original papers in peer-reviewed journals, 215 chapters or monographs, and 490 abstracts. Among his editorial responsibilities, Dr. Kloner serves as editor-in-chief of the Journal of Cardiovascular Pharmacology and Therapeutics and as Guest Editor of Circulation.
Jordan Warshafsky – Business Advisor
Jordan has over 25 years of life science industry experience with an extensive background in pharmaceuticals, medical devices and biotechnology. A co-creator of the Life Sciences Talent Bank, he has previously held industry senior corporate-level leadership positions in business development, global marketing and strategic planning to include being the President of a start-up life science company. Jordan is the company “ambassador” and can be found at many of the region’s Life Sciences Industry meetings. He is married with three wonderful sons, enjoys travelling internationally and spending time with friends and family.
Harold R. Werner, MBA – Business Advisor
Harold R. Werner is a General Partner and Founder of HealthCare Ventures LLC. HealthCare Ventures LLC manages one of the largest venture capital funds devoted exclusively to healthcare products and technologies. Healthcare Ventures has created over fifty pharmaceutical and related health care companies. Mr. Werner has been involved over forty years in the planning, development, and financing of health care technology. Since co-founding HealthCare Ventures in 1985, he has served on the Boards of over forty public and private health care companies and has specialized in the formation of new high-science companies. Prior to the formation of HealthCare Ventures, Mr. Werner was Director of New Ventures for Johnson & Johnson Development Corporation, making outside investments and licenses for Johnson & Johnson in biotechnology, pharmaceuticals, vision care, diagnostics and other high technology areas of health care. Before joining Johnson & Johnson in 1980, Mr. Werner was Senior Vice President of Robert S. First, Inc., and was responsible for managing its European and, later, U.S. health care management consulting business. Mr. Werner received his B.S. (high honors) and M.S. degrees from Princeton University and an M.B.A. from the Harvard Graduate School of Business Administration.